Form 4: Cencora CFO Exercises Stock Options, Sells Shares to Cover Costs

Cencora's Chief Financial Officer, James F. Cleary, exercised stock options and sold a portion of the acquired shares to cover the exercise price and tax obligations.

Summary

• James F. Cleary, the Chief Financial Officer of Cencora, Inc., exercised 33,877 non-qualified stock options on November 27, 2024, at a price of $89.58 per share.
• Following the exercise, Mr. Cleary sold 22,215 shares at a price of $249.07 per share to cover the exercise cost and associated tax obligations.
• After these transactions, Mr. Cleary directly owns 149,293.3479 shares of Cencora common stock.
• The stock options were granted on November 16, 2018, and were exercisable in four equal annual installments starting November 14, 2019.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The exercise of options is a positive sign, but the sale of shares is a routine transaction. There is no indication of any negative sentiment.

Positives

• The exercise of stock options indicates the CFO's confidence in the company's future performance.
• The sale of shares at $249.07 per share suggests a positive market valuation of Cencora stock.

Negatives

• The sale of 22,215 shares by the CFO could be interpreted as a slight reduction in his direct stake in the company, although this is primarily for tax and exercise cost purposes.

Risks

• There is a risk that future stock sales by insiders could negatively impact the stock price if perceived as a lack of confidence in the company.
• The market may react negatively to insider selling, even if it is for routine financial management.

Industry Context

This is a routine transaction for a company with stock-based compensation plans. It is common for executives to exercise options and sell shares to cover costs and taxes.

Comparison to Industry Standards

• Stock option exercises and subsequent sales are a common practice among executives in publicly traded companies, particularly in the pharmaceutical distribution industry.
• Companies like McKesson and Cardinal Health also have similar stock-based compensation plans for their executives, and their executives regularly file Form 4s for similar transactions.
• The sale price of $249.07 per share is a reflection of the current market valuation of Cencora, which is in line with industry trends.

Stakeholder Impact

• The transaction has a minor impact on shareholders, as it involves the sale of shares by an executive.
• The sale of shares could slightly increase the float of the stock.

Key Dates

Keywords

Cencora, Stock Options, Insider Trading, Form 4, James F. Cleary, Chief Financial Officer, Share Sale, Equity Compensation